Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 01, 2025 08:55 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech to Participate in Live ‘Fireside’ Chat on Virtual Investor Closing Bell Series

OCALA, Fla., Dec. 01, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) announced today that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will...
November 25, 2025 08:00 ET | Source: Immuneering Corporation

Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference

Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference
November 19, 2025 11:06 ET | Source: Research and Markets

Oncology Collaboration and Licensing Analysis Report and Directory 2025: Upfront, Milestone, and Royalties for 3,000+ Deals by Company A-Z, Therapy Focus and Technology Type

Dublin, Nov. 19, 2025 (GLOBE NEWSWIRE) -- The "Oncology Collaboration and Licensing Deals 2020-2025" has been added to ResearchAndMarkets.com's offering.Fully revised and updated, the report...
November 18, 2025 08:55 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Reports Third Quarter 2025 Financial Results and Highlights Continued Progress Across Pipeline with Strategic Focus on Pancreatic Cancer Clinical Program

OCALA, Fla., Nov. 18, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today provided a business update and reported its financial results for the third...
November 06, 2025 07:35 ET | Source: Urteste S.A.

Urteste S.A. launches European multicenter clinical study of the Panuri test

Urteste S.A. launches European multicenter clinical study of the Panuri test Gdańsk, Poland – 6 November 2025 – Urteste S.A. (Warsaw Stock Exchange: URT), a company specializing in the development...
October 24, 2025 11:45 ET | Source: Quanta Therapeutics, Inc.

Quanta Therapeutics Presents Positive Phase 1 Data for QTX3034, an Oral G12D-Preferring Multi-KRAS Inhibitor, in Patients with Advanced Solid Tumors

Quanta presented positive Phase 1 data for QTX3034, an oral G12D-preferring multi-KRAS inhibitor, in patients with advanced cancer, including CRC, PDAC
October 23, 2025 08:00 ET | Source: Moleculin Biotech, Inc.

Moleculin Announces New Investigator-Initiated Study of Annamycin for Treating Pancreatic Cancer

Atlantic Health, a leading provider of health care based in New Jersey, to conduct the investigator-initiated Phase 1B/2 study Preclinical studies indicate Annamycin targets key factors in pancreatic...
October 22, 2025 07:00 ET | Source: Galera Therapeutics

Galera Therapeutics Announces Acquisition of Dismutase Mimetics Portfolio by Toronto-based Biossil for up to $105 Million

Galera Therapeutics Announces Acquisition of Avasopasem and the Dismutase Mimetics Portfolio by Toronto-based Biossil for up to $105 Million
October 20, 2025 09:15 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech to Attend the 2025 Maxim Growth Summit

OCALA, Fla., Oct. 20, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced it will participate at the 2025 Maxim Growth Summit, taking place...
September 26, 2025 16:01 ET | Source: Immuneering Corporation

Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025

NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced that it will host a...